Just yesterday, NeuroBo’s stock was at $2.73. However, today it is gaining momentum as stock is surging in the pre-market: it is currently at $4.2, resulting in a 54% gain. The company has recently announced the results of the elections at its Annual Meeting of Shareholders on July 9, 2021, during which Hyung Heon Kim and Andrew I. Koven got elected to the Company’s Board of Directors.
Akash Bakshi nor Jeong Gyun Oh were for re-election at the Annual Meeting. The Board would like to thank Mr. Bakshi and Mr. Oh for their work. The NeuroBo Board now consists of seven directors, six of whom are independent.
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19.
Agneta is still enjoying her trips to Asia and Africa while she works at Own Snap as an author and reporter. Very soon she will settle somewhere in Europe and run her startup enterprise.